Dr. Matthew Rettig

Dr. Matthew B. Rettig, MD, is a nationally recognized medical oncologist specializing in genitourinary cancers, including prostate, kidney, and bladder malignancies. He serves as Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA and holds the role of Medical Director of the Prostate Cancer Program at the UCLA Institute of Urologic Oncology. He is also Chief of Hematology-Oncology at the Greater Los Angeles VA Healthcare System. Dr. Rettig earned his medical degree from Duke University School of Medicine and completed his internal medicine residency and hematology-oncology fellowship at UCLA, where he continues to lead in both clinical and academic spheres.

Dr. Rettig’s clinical and research expertise lies in the development of novel therapies and biomarker-driven strategies for advanced prostate cancer. His research focuses on androgen receptor biology, mechanisms of therapeutic resistance, and immunotherapy in prostate and other genitourinary cancers. He is the principal investigator of numerous clinical trials funded by the NIH, Department of Defense, and industry, and his work has been widely published in leading peer-reviewed journals. Through translational research, he has helped identify key genetic and molecular targets that are now influencing personalized treatment approaches in advanced prostate cancer care.

In addition to his scientific and clinical achievements, Dr. Rettig is a highly regarded educator and mentor, training the next generation of oncologists and physician-scientists at UCLA and the VA. He is actively involved in national organizations such as the American Society of Clinical Oncology and the American Urological Association, where he contributes to guideline development and clinical trial leadership. Known for his compassionate approach to care, Dr. Rettig is consistently ranked among the region’s top doctors and is deeply committed to advancing outcomes for patients facing genitourinary cancers.